206-838-5110 ext. 102 general@etubics.com

Press Releases

Etubics Enters Phase 1 Cancer Clinical Trials Focused on Colorectal Cancer

SEATTLE (July 28, 2010) - Etubics Corporation, a development stage biopharmaceutical company developing "next generation" vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen (CEA)-expressing cancers such as colorectal cancer.

Archives

Media Contact:

Jen Hodson
NantWorks
562-397-3639
Press@NantHealth.com